BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 26479923)

  • 1. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
    Gao H; Korn JM; Ferretti S; Monahan JE; Wang Y; Singh M; Zhang C; Schnell C; Yang G; Zhang Y; Balbin OA; Barbe S; Cai H; Casey F; Chatterjee S; Chiang DY; Chuai S; Cogan SM; Collins SD; Dammassa E; Ebel N; Embry M; Green J; Kauffmann A; Kowal C; Leary RJ; Lehar J; Liang Y; Loo A; Lorenzana E; Robert McDonald E; McLaughlin ME; Merkin J; Meyer R; Naylor TL; Patawaran M; Reddy A; Röelli C; Ruddy DA; Salangsang F; Santacroce F; Singh AP; Tang Y; Tinetto W; Tobler S; Velazquez R; Venkatesan K; Von Arx F; Wang HQ; Wang Z; Wiesmann M; Wyss D; Xu F; Bitter H; Atadja P; Lees E; Hofmann F; Li E; Keen N; Cozens R; Jensen MR; Pryer NK; Williams JA; Sellers WR
    Nat Med; 2015 Nov; 21(11):1318-25. PubMed ID: 26479923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
    Altunel E; Roghani RS; Chen KY; Kim SY; McCall S; Ware KE; Shen X; Somarelli JA; Hsu DS
    BMC Cancer; 2020 Jun; 20(1):592. PubMed ID: 32580713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived melanoma models.
    Karras F; Kunz M
    Pathol Res Pract; 2024 Jul; 259():155231. PubMed ID: 38508996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
    Townsend EC; Murakami MA; Christodoulou A; Christie AL; Köster J; DeSouza TA; Morgan EA; Kallgren SP; Liu H; Wu SC; Plana O; Montero J; Stevenson KE; Rao P; Vadhi R; Andreeff M; Armand P; Ballen KK; Barzaghi-Rinaudo P; Cahill S; Clark RA; Cooke VG; Davids MS; DeAngelo DJ; Dorfman DM; Eaton H; Ebert BL; Etchin J; Firestone B; Fisher DC; Freedman AS; Galinsky IA; Gao H; Garcia JS; Garnache-Ottou F; Graubert TA; Gutierrez A; Halilovic E; Harris MH; Herbert ZT; Horwitz SM; Inghirami G; Intlekofer AM; Ito M; Izraeli S; Jacobsen ED; Jacobson CA; Jeay S; Jeremias I; Kelliher MA; Koch R; Konopleva M; Kopp N; Kornblau SM; Kung AL; Kupper TS; LeBoeuf NR; LaCasce AS; Lees E; Li LS; Look AT; Murakami M; Muschen M; Neuberg D; Ng SY; Odejide OO; Orkin SH; Paquette RR; Place AE; Roderick JE; Ryan JA; Sallan SE; Shoji B; Silverman LB; Soiffer RJ; Steensma DP; Stegmaier K; Stone RM; Tamburini J; Thorner AR; van Hummelen P; Wadleigh M; Wiesmann M; Weng AP; Wuerthner JU; Williams DA; Wollison BM; Lane AA; Letai A; Bertagnolli MM; Ritz J; Brown M; Long H; Aster JC; Shipp MA; Griffin JD; Weinstock DM
    Cancer Cell; 2016 Apr; 29(4):574-586. PubMed ID: 27070704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.
    Bruna A; Rueda OM; Greenwood W; Batra AS; Callari M; Batra RN; Pogrebniak K; Sandoval J; Cassidy JW; Tufegdzic-Vidakovic A; Sammut SJ; Jones L; Provenzano E; Baird R; Eirew P; Hadfield J; Eldridge M; McLaren-Douglas A; Barthorpe A; Lightfoot H; O'Connor MJ; Gray J; Cortes J; Baselga J; Marangoni E; Welm AL; Aparicio S; Serra V; Garnett MJ; Caldas C
    Cell; 2016 Sep; 167(1):260-274.e22. PubMed ID: 27641504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrogating open issues in cancer precision medicine with patient-derived xenografts.
    Byrne AT; Alférez DG; Amant F; Annibali D; Arribas J; Biankin AV; Bruna A; Budinská E; Caldas C; Chang DK; Clarke RB; Clevers H; Coukos G; Dangles-Marie V; Eckhardt SG; Gonzalez-Suarez E; Hermans E; Hidalgo M; Jarzabek MA; de Jong S; Jonkers J; Kemper K; Lanfrancone L; Mælandsmo GM; Marangoni E; Marine JC; Medico E; Norum JH; Palmer HG; Peeper DS; Pelicci PG; Piris-Gimenez A; Roman-Roman S; Rueda OM; Seoane J; Serra V; Soucek L; Vanhecke D; Villanueva A; Vinolo E; Bertotti A; Trusolino L
    Nat Rev Cancer; 2017 Apr; 17(4):254-268. PubMed ID: 28104906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived xenografts undergo mouse-specific tumor evolution.
    Ben-David U; Ha G; Tseng YY; Greenwald NF; Oh C; Shih J; McFarland JM; Wong B; Boehm JS; Beroukhim R; Golub TR
    Nat Genet; 2017 Nov; 49(11):1567-1575. PubMed ID: 28991255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer: Xenograft encyclopaedia identifies drug combination opportunities.
    Cully M
    Nat Rev Drug Discov; 2015 Dec; 14(12):818. PubMed ID: 26585532
    [No Abstract]   [Full Text] [Related]  

  • 9. Personalized
    Pauli C; Hopkins BD; Prandi D; Shaw R; Fedrizzi T; Sboner A; Sailer V; Augello M; Puca L; Rosati R; McNary TJ; Churakova Y; Cheung C; Triscott J; Pisapia D; Rao R; Mosquera JM; Robinson B; Faltas BM; Emerling BE; Gadi VK; Bernard B; Elemento O; Beltran H; Demichelis F; Kemp CJ; Grandori C; Cantley LC; Rubin MA
    Cancer Discov; 2017 May; 7(5):462-477. PubMed ID: 28331002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.
    Meehan TF; Conte N; Goldstein T; Inghirami G; Murakami MA; Brabetz S; Gu Z; Wiser JA; Dunn P; Begley DA; Krupke DM; Bertotti A; Bruna A; Brush MH; Byrne AT; Caldas C; Christie AL; Clark DA; Dowst H; Dry JR; Doroshow JH; Duchamp O; Evrard YA; Ferretti S; Frese KK; Goodwin NC; Greenawalt D; Haendel MA; Hermans E; Houghton PJ; Jonkers J; Kemper K; Khor TO; Lewis MT; Lloyd KCK; Mason J; Medico E; Neuhauser SB; Olson JM; Peeper DS; Rueda OM; Seong JK; Trusolino L; Vinolo E; Wechsler-Reya RJ; Weinstock DM; Welm A; Weroha SJ; Amant F; Pfister SM; Kool M; Parkinson H; Butte AJ; Bult CJ
    Cancer Res; 2017 Nov; 77(21):e62-e66. PubMed ID: 29092942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Landscape of Pharmacogenomic Interactions in Cancer.
    Iorio F; Knijnenburg TA; Vis DJ; Bignell GR; Menden MP; Schubert M; Aben N; Gonçalves E; Barthorpe S; Lightfoot H; Cokelaer T; Greninger P; van Dyk E; Chang H; de Silva H; Heyn H; Deng X; Egan RK; Liu Q; Mironenko T; Mitropoulos X; Richardson L; Wang J; Zhang T; Moran S; Sayols S; Soleimani M; Tamborero D; Lopez-Bigas N; Ross-Macdonald P; Esteller M; Gray NS; Haber DA; Stratton MR; Benes CH; Wessels LFA; Saez-Rodriguez J; McDermott U; Garnett MJ
    Cell; 2016 Jul; 166(3):740-754. PubMed ID: 27397505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts.
    Cho SY; Kang W; Han JY; Min S; Kang J; Lee A; Kwon JY; Lee C; Park H
    Mol Cells; 2016 Feb; 39(2):77-86. PubMed ID: 26831452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.
    Izumchenko E; Paz K; Ciznadija D; Sloma I; Katz A; Vasquez-Dunddel D; Ben-Zvi I; Stebbing J; McGuire W; Harris W; Maki R; Gaya A; Bedi A; Zacharoulis S; Ravi R; Wexler LH; Hoque MO; Rodriguez-Galindo C; Pass H; Peled N; Davies A; Morris R; Hidalgo M; Sidransky D
    Ann Oncol; 2017 Oct; 28(10):2595-2605. PubMed ID: 28945830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic agreement between two cancer cell line data sets.
    ;
    Nature; 2015 Dec; 528(7580):84-7. PubMed ID: 26570998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
    Huang L; Holtzinger A; Jagan I; BeGora M; Lohse I; Ngai N; Nostro C; Wang R; Muthuswamy LB; Crawford HC; Arrowsmith C; Kalloger SE; Renouf DJ; Connor AA; Cleary S; Schaeffer DF; Roehrl M; Tsao MS; Gallinger S; Keller G; Muthuswamy SK
    Nat Med; 2015 Nov; 21(11):1364-71. PubMed ID: 26501191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
    Bradford JR; Wappett M; Beran G; Logie A; Delpuech O; Brown H; Boros J; Camp NJ; McEwen R; Mazzola AM; D'Cruz C; Barry ST
    Oncotarget; 2016 Apr; 7(15):20773-87. PubMed ID: 26980748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived xenografts as tools in pharmaceutical development.
    Izumchenko E; Meir J; Bedi A; Wysocki PT; Hoque MO; Sidransky D
    Clin Pharmacol Ther; 2016 Jun; 99(6):612-21. PubMed ID: 26874468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
    Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
    FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field.
    Williams JA
    J Clin Med; 2018 Mar; 7(3):. PubMed ID: 29498669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour exosome integrins determine organotropic metastasis.
    Hoshino A; Costa-Silva B; Shen TL; Rodrigues G; Hashimoto A; Tesic Mark M; Molina H; Kohsaka S; Di Giannatale A; Ceder S; Singh S; Williams C; Soplop N; Uryu K; Pharmer L; King T; Bojmar L; Davies AE; Ararso Y; Zhang T; Zhang H; Hernandez J; Weiss JM; Dumont-Cole VD; Kramer K; Wexler LH; Narendran A; Schwartz GK; Healey JH; Sandstrom P; Labori KJ; Kure EH; Grandgenett PM; Hollingsworth MA; de Sousa M; Kaur S; Jain M; Mallya K; Batra SK; Jarnagin WR; Brady MS; Fodstad O; Muller V; Pantel K; Minn AJ; Bissell MJ; Garcia BA; Kang Y; Rajasekhar VK; Ghajar CM; Matei I; Peinado H; Bromberg J; Lyden D
    Nature; 2015 Nov; 527(7578):329-35. PubMed ID: 26524530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.